Latest market price
32.24
-0.27-0.83%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.66 | Insider Own | — | Shs Outstand | 33.45M | Perf Week | 13.20% |
| Market Cap | 1.08B | Forward P/E | — | EPS next Y | -2.81 | Insider Trans | — | Shs Float | 13.97M | Perf Month | 21.66% |
| Enterprise Value | 846.36M | PEG | — | EPS next Q | -0.66 | Short Float | 8.77% | Perf Quarter | 42.15% | ||
| Income | -57.00M | P/S | — | EPS this Y | — | Short Ratio | 12.15 | Perf Half Y | 34.45% | ||
| Sales | 0.00 | P/B | 4.65 | EPS next Y | — | ROA | -23.03% | Short Interest | 1.22M | Perf YTD | 34.33% |
| Book/sh | 6.94 | P/C | 4.61 | EPS next 5Y | — | ROE | -75.64% | 52W High | 33.84 -4.73% | Perf Year | — |
| Cash/sh | 7.00 | P/FCF | — | EPS past 3/5Y | — | ROIC | -26.54% | 52W Low | 17.06 88.98% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 6.97% 6.09% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 1.71 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 25.06 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 71.39 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 25.06 | EPS Q/Q | 14.49% | SMA20 | 19.72% | Beta | 1.38 | Target Price | 38.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | 18.41% | Rel Volume | 0.92 | Prev Close | 32.51 |
| Employees | 76 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | 32.33% | Avg Volume | 102.19K | Price | 32.24 |
| IPO Date | Feb 06, 2026 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -14.69% — | Net Debt/EBITDA | — | Volume | 94,146 | Change | -0.83% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-05-26 | Reiterated | HC Wainwright & Co. | Buy | $37 |
| Aug-14-26 | Initiated | Raymond James | Outperform | $39 |
| Mar-03-26 | Reiterated | Jefferies | $62 |
Latest News· Times ET
Oct-21-26
Oct-21-2603:50AM
Oct-19-26
Oct-19-2608:00AM
Oct-14-26
Oct-14-2605:01PM
Oct-05-26
Oct-05-2604:01AM
Oct-01-26
Oct-01-2608:00AM
Sep-10-26
Sep-10-2602:37PM
Sep-02-26
Aug-14-26
Aug-14-2607:55AM
04:57AM
Aug-06-26
Aug-06-2604:05PM
Jul-26-26
Jul-25-26
Jul-25-2604:43AM
Company
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | |
|---|---|---|---|
| Total Revenue | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 1 | |
| Gross Profit | 0 | -1 | |
| Selling, General and Administrative Excl. Other | 27 | 12 | |
| Research and Development | 35 | 29 | |
| Other Operating Expense | -1 | 0 | |
| Operating Income | -62 | -41 | |
| Interest Expense | 0 | 0 | |
| Unusual Expense | — | — | |
| Non-Operating Income (Expense) | 6 | 2 | |
| Net Income Before Taxes | -57 | -40 | |
| Income Taxes | 0 | 0 | |
| Consolidated Net Income | -57 | -40 | |
| Net Income From Continuing Operations | -57 | -40 | |
| Net Income | -57 | -40 | |
| EPS (Recurring) | -1.66 | -1.25 | |
| EPS (Basic, Before Extraordinaries) | -1.66 | -1.25 | |
| EPS (Diluted) | -1.66 | -1.25 | |
| EBITDA | -58 | -39 | |
| Other After Tax Adjustments | — | — | |
| Stock Option Compensation Expense | — | — | |
| Price To Earnings Ratio | — | — | |
| Price To Sales Ratio | — | — | |
| Gross Margin | — | — | |
| Operating Margin | — | — | |
| Net Margin | — | — | |
| Shares Outstanding | 33 | 32 | |
| Market Capitalization | 1,064 | — | |
| Operating Lease Expense | — | — |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.